Serum biomarkers and non-invasive indices for discriminating MASLD among adults with dysglycaemia
Authors:
Open Access
- 1 January 2026
- journal article
- Published by Walter de Gruyter GmbH in Open Medicine
- Vol. 21 (1) , 20261556
Abstract
Objectives: Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide. Although dysglycaemia is a major risk factor, additional cardiometabolic disturbances contribute to the development of MASLD. This study aimed to identify parameters that distinguish MASLD among dysglycaemic individuals using body composition, anthropometric, biochemical, and imaging-based assessments. Methods: In this cross-sectional study, male and female adults were stratified into three groups: dysglycaemic individuals with MASLD (MASLD-Dys), dysglycaemic individuals without MASLD (Dys), and normoglycaemic individuals without MASLD as healthy controls. Imaging-based hepatic fat quantification, body composition, anthropometric and biochemical parameters, and non-invasive indices assessing hepatic steatosis and fibrosis were evaluated. Results: Compared with Dys participants, MASLD-Dys participants had higher body mass index (BMI), waist circumference, trunk fat mass, ultrasound-derived hepatic fat fraction (USFF), and Fatty Liver Index (FLI). The strongest between-group separation was observed for USFF (p<0.001). In receiver operating characteristic analysis, USFF showed the highest discriminative performance for MASLD-Dys vs. Dys, with an area under the curve of 0.925 and an optimal cut-off of ≥6.95 %. Conclusions: USFF was the strongest discriminator of MASLD among dysglycaemic adults, while FLI provided a practical non-imaging alternative. These findings support integrating hepatic fat quantification and body composition measures into MASLD risk stratification beyond glycaemic status alone.Keywords
This publication has 47 references indexed in Scilit:
- Risk Reclassification Beyond BMI by Waist Circumference and Waist-to-Hip Ratio Across 9 Cardiovascular OutcomesJACC, 2026
- Global Prevalence of Nonalcoholic Fatty Liver Disease: An Updated Review Meta-Analysis comprising a Population of 78 million from 38 CountriesArchives of Medical Research, 2024
- Non‐invasive assessment of hepatic steatosis by ultrasound‐derived fat fraction in individuals at high‐risk for metabolic dysfunction‐associated steatotic liver diseaseDiabetes/Metabolism Research and Reviews, 2024
- Interobserver Variability in Ultrasound‐Based Liver Fat QuantificationJournal of Ultrasound in Medicine, 2022
- From NAFLD to MAFLD: Implications of a Premature Change in TerminologyHepatology, 2020
- Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic DiseasesCell Metabolism, 2018
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver DiseasesHepatology, 2017
- The NAFLD fibrosis scoreHepatology, 2007
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionHepatology, 2006
- Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in manDiabetologia, 1985